Smonporn Boonyaratavej

Smonporn Boonyaratavej

Auto-generated profile, based on publicly available information

Smonporn Boonyaratavej

Division of Cardiovascular Medicine, Department of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in JACC
Verified
Journal Article
Closed access
SBSmonporn Boonyaratavej
Smonporn Boonyaratavej
JOJae K Oh
Jae K Oh
ATA.JAmil Tajik
A.JAmil Tajik
CAChristopher P Appleton
Christopher P Appleton
JSJames B Seward
James B Seward

22 November 2012 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
KSKittiwan Sumethkul
Kittiwan Sumethkul
SBSmonporn Boonyaratavej
Smonporn Boonyaratavej
TKTasanee Kitumnuaypong
Tasanee Kitumnuaypong
SASungchai Angthararuk
Sungchai Angthararuk
PCPatcharin Cheewasat
Patcharin Cheewasat
VSVasant Sumethkul
Vasant Sumethkul

30 September 2010 in Global Heart
Verified
Journal Article
Closed access
PLPrasart Laothavorn
Prasart Laothavorn
KHKriengkrai Hengrussamee
Kriengkrai Hengrussamee
RKRungsrit Kanjanavanit
Rungsrit Kanjanavanit
WMWorachat Moleerergpoom
Worachat Moleerergpoom
DLDonpichit Laorakpongse
Donpichit Laorakpongse
OGOn Behalf Of Thai Adhere Registry Working Groups
On Behalf Of Thai Adhere Registry Working Groups
Results There were 2041 HF admissions in 1612 patients with a median age of 67 years (mean 64 ± 14 years). Age >75 years was found in 24%, 49.6% were male patients, and 67% of these admissions had prior heart failure. Underlying diseases were hypertension [(HT) = 65%], coronary artery disease [(CAD) = 47%], dyslipidemia (50%), diabetes mellitus (47%), atrial fibrillation (24%) and chronic kidney disease (19%). Clinical features at presentation were dyspnea (97%), edema (60%), pulmonary rales (85%) and pulmonary congestion by chest X-ray (93%). Sixty-nine percent (69%) were in NYHA functional class IV and 44% had a left ventricular ejection fraction (LVEF) less than 40%. Common causes of heart failure were CAD (45%), valvular heart diseases (19%), cardiomyopathy (14%) and HT (12%). Precipitating causes of heart failure were heart disease itself 54% and 20% were related to inadequate diuretics and poor patient compliance with medications. Neurohormonal blockers (NHB) [angiotensin converting enzyme inhibitors (ACEI), angiotensinoge receptor blocker (ARB), aldosterone blocker (AA) and beta blockers (BB)], were given prior to hospitalization in comparison to at discharge in 26% vs. 35%, 12% vs. 12%, 13% vs. 17% and 26% vs. 24% respectively. In-hospital mortality rate was 5.5% and the median length of hospitalization was 7.5 days. Major causes of death were sepsis, worsening of heart failure, arrhythmic arrest and acute coronary syndrome. There was a higher mortality rate in those with poor LV systolic function compared to those with preserved LV systolic function (8.2% vs. 4.1%; p = .008). At discharge, 23% of the patients were asymptomatic while 69% had symptomatic improvement. Conclusion Thai ADHERE registry revealed that Thai patients hospitalized for heart failure are younger and sicker than European and American patients. There is a high prevalence of HF with preserved ejection fraction. CAD was the most common cause of HF while HT was the most common underlying disease. There was a 5.4% mortality rate, which was higher in those with poor LV systolic function. There was underutilization of NHB (ACEI, ARB, BB and AA). Keywords Thai ADHERE registry Heart failure Thai heart failure registry Neurohormonal blockers Introduction Heart failure is the one of the malignant cardiac syndromes which has a high morbidity and mortality rate all over the world. In Thailand, heart failure is one of the major cardiovascular health problems and economic burdens. In Europe, the prevalence of symptomatic heart failure (HF) is estimated to range from 0.4% to 2.0% [1] in the general population and the mean age of the HF population is 70 years [1,2] . In the US, data from Heart Disease and Stroke Statistics_2009 Update [3] indicate that: HF incidence approaches 10 per 1000 population after 65 years of age. Seventy-five percent of HF cases have antecedent hypertension follow closely by antecedent myocardial infarction. The range in incidence is 3.4–6.0 in whites and 8.1–9.1 in blacks per 1000 person-years. In 2005, 1 in 8 death certificates (292,214 deaths) in the United States mentioned heart failure. In Thailand there has been no epidemiologic HF data. This is the first epidemiologic study of heart failure in Thailand using the same protocol as the US ADHERE Registry [4,8] . The aim of this study is to assess the database of hospitalized patients with the diagnosis of heart failure (HF) or acute decompensated heart failure (ADHF) in Thailand in terms of patient characteristics, clinical presentations, and causes of heart failure, precipitating causes of heart failure, hospital course, management and hospital outcomes. This registry includes 18 participating cardiac centers (10 university hospitals, 3 government hospitals and five private hospitals). The Thai ADHERE investigators hope that this data will give information about heart failure management. The data should help us to improve our heart failure management, applying appropriate practice guidelines for HF and lowering the mortality and morbidity from HF in Thailand. Materials and methods Thai Acute Decompensate Heart Failure Registry or Thai ADHERE registry is a phase IV multi-center prospective observational and open-label registry study. Methods are the same as US ADHERE [4,8] . In brief, it enrolled consecutively hospitalized patients age more than 18 years with a post discharge diagnosis of HF in 18 cardiovascular centers from March 2006 to November 2007. Patients with cardiogenic shock, perioperative heart failure and the patients who present HF as a co-morbid condition but not a principal focus of diagnosis or treatment were excluded. Data were collected from each medical summary beginning with the point of initial care and/or emergency department and ending when the patient was discharged or transferred out of the hospital or in-hospital death. Heart failure (HF) or decompensated HF was determined clinically by the cardiologists. ADHF is clinically defined as new-onset HF with decompensation or chronic HF with decompensation. Entry was based upon the presence of ADHF and not tied to the use of any specific therapeutic agent or regimen. Each institution was instructed to identify and capture all consecutive eligible subjects. Data collection Data, captured via the case record form (CRF), include demographic characteristics, medical history, initial evaluation, clinical presentations, hospital course, medications given prior to admission and at discharge, procedures, disposition status, discharge instruction, causes and precipitating causes of heart failure and mortality. The data were collected via a web-based electronic data capture (EDC) system provided by Scios company. Participating centers entered data via customized electronic case report forms and all data were checked for validity. To preserve patient’s anonymity, there was no collection of unique patient identifying information. The Longitudinal Unique...

6 April 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
PSPatita Sitticharoenchai
Patita Sitticharoenchai
KTKullaya Takkavatakarn
Kullaya Takkavatakarn
SBSmonporn Boonyaratavej
Smonporn Boonyaratavej
KPKearkiat Praditpornsilpa
Kearkiat Praditpornsilpa
SESomchai Eiam-Ong
Somchai Eiam-Ong
PSPaweena Susantitaphong
Paweena Susantitaphong
Background: Non‐vitamin K antagonist oral anticoagulants (NOACs) have better pharmacologic properties than warfarin and are recommended in preference to warfarin in most patients with non‐valvular atrial fibrillation. Besides lower bleeding complications, other advantages of NOACs over warfarin particularly renal outcomes remain inconclusive. Methods and Results: Electronic searches were conducted through Medline, Scopus, Cochrane Library databases, and ClinicalTrial.gov. Randomized controlled trials and observational cohort studies reporting incidence rates and hazard ratio (HR) of renal outcomes (including acute kidney injury, worsening renal function, doubling serum creatinine, and end‐stage renal disease) were selected. The random‐effects model was used to calculate pooled incidence and HR with 95% CI. Eighteen studies were included. A total of 285 201 patients were enrolled, 118 863 patients with warfarin and 166 338 patients with NOACs. The NOACs group yielded lower incidence rates of all renal outcomes when compared with the warfarin group. Patients treated with NOACs showed significantly lower HR of risk of acute kidney injury (HR, 0.70, 95% CI, 0.64–0.76; P <0.001), worsening renal function (HR, 0.83; 95% CI, 0.73–0.95; P =0.006), doubling serum creatinine (HR, 0.58; 95% CI, 0.41–0.82; P =0.002), and end‐stage renal disease (HR, 0.82; 95% CI, 0.78–0.86; P <0.001). Conclusions: In non‐valvular atrial fibrillation, patients treated with NOACs have a lower risk of both acute kidney injury and end‐stage renal disease when compared with warfarin.

1 April 2012
Verified
Journal Article
Closed access
SSSuphot Srimahachota
Suphot Srimahachota
SBSmonporn Boonyaratavej
Smonporn Boonyaratavej
RKRungsrit Kanjanavanit
Rungsrit Kanjanavanit
PSPiyamitr Sritara
Piyamitr Sritara
RKRungroj Krittayaphong
Rungroj Krittayaphong
PTPyatat Tatsanavivat
Pyatat Tatsanavivat

1 October 2007
Verified
Journal Article
Closed access
SSSuphot Srimahachota
Suphot Srimahachota
RKRungsrit Kanjanavanit
Rungsrit Kanjanavanit
SBSmonporn Boonyaratavej
Smonporn Boonyaratavej
WBWatana Boonsom
Watana Boonsom
GVGumpanart Veerakul
Gumpanart Veerakul
DTDamras Tresukosol
Damras Tresukosol